Behçet's disease ocular attack score 24: Evaluation of ocular disease activity before and after initiation of infliximab

Japanese Journal of Ophthalmology

Volumn 58, Issue 2, 2014, Pages 120-130

  Kaburaki, Toshikatsu ^a   Namba, Kenichi ^b   Sonoda, Koh Hei ^c   Kezuka, Takeshi ^d   Keino, Hiroshi ^e   Fukuhara, Takako ^b,f   Kamoi, Koju ^g   Nakai, Kei ^h   Mizuki, Nobuhisa ⁱ   Ohguro, Nobuyuki ^j  

^a UNIVERSITY OF TOKYO   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Tokyo Medical University School of Medicine   (Japan)

^e KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f KYUSHU UNIVERSITY   (Japan)

^g TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^h OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ YOKOHAMA CITY UNIVERSITY   (Japan)

^j OSAKA KOSEI NENKIN HOSPITAL   (Japan)

more..

Author keywords

Beh et's disease; Disease activity; Infliximab; Ocular attack; Score

Indexed keywords

COLCHICINE; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB;

ADULT; ANTERIOR EYE CHAMBER; ARTICLE; BEHCET DISEASE; BEHCET DISEASE OCULAR ATTACK SCORE 24; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE SEVERITY; EYE INFLAMMATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; TREATMENT OUTCOME; UVEITIS; UVEORETINITIS; VALIDITY; VISUAL ANALOG SCALE; VITREOUS OPACITY; YOUNG ADULT;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; BEHCET SYNDROME; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOMETRICS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE; UVEITIS; YOUNG ADULT;

EID: 84896495867     PISSN: 00215155     EISSN: 16132246     Source Type: Journal    
DOI: 10.1007/s10384-013-0294-0     Document Type: Article

References (20)

1. Ohguro N, Sonoda KH, Takeuchi M, Matsumura M, Mochizuki M. The 2009 prospective multi-center epidemiologic survey of uveitis in Japan. Jpn J Ophthalmol. 2012;56:432-5.
2. Nakae K, Masaki F, Hashimoto F, Inaba G, Mochizuki M, Sakane T. Recent epidemiological features of Behçet's disease in Japan. In: Godeau P, Wechsler B, editors. Behçet's disease. Amsterdam: Excerpta Medica; 1993. p. 145-51.
3. Mochizuki M, Akduman L, Nussenblatt RB. Behçet disease. In: Pepose JS, Holland GN, Wilhelmus KR, editors. Ocular infection and immunity. St. Louis: Mosby; 1996. p. 663-75.
4. Evereklioglu C. Current concepts in the etiology and treatment of Behçet disease. Surv Ophthalmol. 2005;50:297-350. (Pubitemid 40828225)
5. Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362-8. (Pubitemid 38879203)
6. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet. 2001;358:295-6. (Pubitemid 32738970)
7. Niccoli L, Nannini C, Benucci M, Chindamo D, Cassarà E, Salvarani C, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: a 24-month follow-up study. Rheumatology. 2007;46:1161-4. (Pubitemid 47050622)
8. Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy. Arthritis Rheum. 2005;52:2513-8.
9. Kawazoe Y, Sugita S, Yamada Y, Akino A, Miura K, Mochizuki M. Psoriasis triggered by infliximab in a patient with Behçet's disease. Jpn J Ophthalmol. 2013;57:95-7.
10. Yoshida A, Kawashima H, Motoyama Y, Shibui H, Kaburaki T, Shimizu K, et al. Comparison of patients with Behcet's disease in the 1980s and 1990s. Ophthalmology. 2004;111:810-5. (Pubitemid 38429681)
11. Okada AA, Goto H, Ohno S, Mochizuki M, Ocular Behçet's Disease Research Group of Japan. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol. 2012;130:592-8.
12. Kaburaki T, Araki F, Takamoto M, Okinaga K, Yoshida A, Numaga J, et al. Best-corrected visual acuity and frequency of ocular attacks during the initial 10 years in patients with Behçet's disease. Graefes Arch Clin Exp Ophthalmol. 2010;248:709-14.
13. Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ. Behçet's disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford). 1999;38:728-33. (Pubitemid 29507389)
14. Lawton G, Bhakta BB, Chamberlain MA, Tennant A. The Behcet's disease activity index. Rheumatology (Oxford). 2004;43:73-8.
15. Gaujoux-Viala C, Mouterde G, Baillet A, Claudepierre P, Fautrel B, Le Loët X, et al. Evaluating disease activity in rheumatoid arthritis: which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI. Joint Bone Spine. 2012;79:149-55.
16. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44-8.
17. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology. 2003;42:244-57. (Pubitemid 36305610)
18. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7:R796-806.
19. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509-16. (Pubitemid 41224845)
20. Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92:467-71. (Pubitemid 15034518)